نمایش مختصر رکورد

dc.date.accessioned1399-07-08T18:15:35Zfa_IR
dc.date.accessioned2020-09-29T18:15:35Z
dc.date.available1399-07-08T18:15:35Zfa_IR
dc.date.available2020-09-29T18:15:35Z
dc.date.issued2014-12-01en_US
dc.date.issued1393-09-10fa_IR
dc.identifier.citation(2014). Synthesis, Characterization and in vitro Anti-Tumoral Evaluation of Erlotinib-PCEC Nanoparticles. Asian Pacific Journal of Cancer Prevention, 15(23), 10281-10287.en_US
dc.identifier.issn1513-7368
dc.identifier.issn2476-762X
dc.identifier.urihttp://journal.waocp.org/article_30260.html
dc.identifier.urihttps://iranjournals.nlai.ir/handle/123456789/39891
dc.description.abstract<b>Background:</b> Development of a nanosized polymeric delivery system for erlotinib was the main objectiveof this research. Materials and <br/><b>Methods</b>: Poly caprolactone-polyethylene glycol-polycaprolactone (PCEC)copolymers with different compositions were synthesized via ring opening polymerization. Formation of triblockcopolymers was confirmed by HNMR as well as FT-IR. Erlotinib loaded nanoparticles were prepared by meansof synthesized copolymers with solvent displacement method. <br/><b>Results</b>: Physicochemical properties of obtainedpolymeric nanoparticles were dependent on composition of used copolymers. Size of particles was decreased withdecreasing the PCL/PEG molar ratio in used copolymers. Encapsulation efficiency of prepared formulationswas declined by decreasing their particle size. Drug release behavior from the prepared nanoparticles exhibiteda sustained pattern without a burst release. From the release profiles, it can be found that erlotinib release ratefrom polymeric nanoparticles is decreased by increase of CL/PEG molar ratio of prepared block copolymers.Based on MTT assay results, cell growth inhibition of erlotinib has a dose and time dependent pattern. After 72hours of exposure, the 50% inhibitory concentration (IC50) of erlotinib hydrochloride was appeared to be 14.8μM. <br/><b>Conclusions</b>: From the obtained results, it can be concluded that the prepared PCEC nanoparticles in thisstudy might have the potential to be considered as delivery system for erlotinib.en_US
dc.format.extent892
dc.format.mimetypeapplication/pdf
dc.languageEnglish
dc.language.isoen_US
dc.publisherWest Asia Organization for Cancer Prevention (WAOCP)en_US
dc.relation.ispartofAsian Pacific Journal of Cancer Preventionen_US
dc.subjecterlotiniben_US
dc.subjectPCECen_US
dc.subjectsolvent displacement methoden_US
dc.subjectNanoparticlesen_US
dc.titleSynthesis, Characterization and in vitro Anti-Tumoral Evaluation of Erlotinib-PCEC Nanoparticlesen_US
dc.typeTexten_US
dc.citation.volume15
dc.citation.issue23
dc.citation.spage10281
dc.citation.epage10287


فایل‌های این مورد

Thumbnail

این مورد در مجموعه‌های زیر وجود دارد:

نمایش مختصر رکورد